Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02097277 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

A Phase 2 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
219
Enrollment target

NCT02097277: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.

NCT02097277 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 219 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02097277, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
219 participants
Enrollment target

Study Summary

The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.

Primary Outcome

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Percent Change in Glycosylated Hemoglobin A1c (HbA1c) from Baseline to Week 12 was reported.

Interventions

  • BIOLOGICAL BMS-986036
  • BIOLOGICAL Placebo (Matching with BMS-986036)

Trial Details

FieldValue
Enrollment Target 219 participants
Start Date 2014-04-15
Est. Completion 2016-05-17
Phase Phase 2
Bristol-Myers Squibb

1,025 total trials

What the finished NCT02097277 record still lists

NCT02097277 is an interventional study that assigns participants to a tested intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher).

The record links to 0 conditions, and to 2 interventions - of which BMS-986036 is the first listed.

NCT02097277 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02097277 about?

NCT02097277 is a clinical study titled "A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes". The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.

What is the current status of trial NCT02097277?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 219 participants. The study started on 2014-04-15. Estimated completion is 2016-05-17.

What interventions are being tested in trial NCT02097277?

The interventions under investigation include: BMS-986036 (BIOLOGICAL), Placebo (Matching with BMS-986036) (BIOLOGICAL).

Who is sponsoring clinical trial NCT02097277?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02097277's enrollment target sits among peer trials

219 283rd of 2000 higher than 1,717 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05196035 · 219 participants · Phase 3

    A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

  • NCT05608434 · 219 participants · Phase 1

    Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

  • NCT05773144 · 219 participants · NA

    Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer

  • NCT05907980 · 219 participants · Phase 1

    A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02097277, the US trial registry maintained by the National Library of Medicine. NCT02097277 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.